

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

Information for the public

Published: 14 November 2018

www.nice.org.uk

Gemtuzumab ozogamicin (Mylotarg), given with daunorubicin and cytarabine, is available on the NHS. It is a possible treatment for untreated de novo CD33-positive acute myeloid leukaemia (AML) in people aged 15 years and over if a cytogenetic test shows that the disease has favourable or intermediate characteristics, or if a cytogenetic test didn't work. It may also be used as induction therapy if cytogenetic test results aren't yet available.

Gemtuzumab ozogamicin should not be used to treat acute promyelocytic leukaemia.

If you are not eligible for gemtuzumab ozogamicin but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Leukaemia Care](#), 08088 010 444
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3157-6